In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today ...
Please provide your email address to receive an email when new articles are posted on . Patients classified with highest risk who were treated with ART had a 50% decrease in metastatic disease ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the ...
FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of ...
“With the expansion of our New York Clinical Laboratory Permit to include our DecisionDx-SCC test, patients in New York will now have access to personalized genomic information, which physicians can ...
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results